Net Cash Provided by (Used in) Operating Activities of Vistagen Therapeutics, Inc. from 30 Jun 2010 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Vistagen Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Operating Activities in USD history and change rate from 30 Jun 2010 to 30 Jun 2025.
  • Vistagen Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 30 Jun 2025 was $18,846,000, a 73% decline year-over-year.
  • Vistagen Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was $42,097,000, a 63% decline from 2023.
  • Vistagen Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was $25,813,000, a 48% increase from 2022.
  • Vistagen Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $49,716,000, a 9.9% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

Vistagen Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $18,846,000 -$7,977,000 -73% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2026 Q1
Q2 2024 $10,869,000 -$2,978,000 -38% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2026 Q1
Q2 2023 $7,891,000 +$8,077,300 +51% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2025 Q1
Q2 2022 $15,968,300 -$9,795,400 -159% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2024 Q1
Q2 2021 $6,172,900 -$3,366,200 -120% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q1
Q2 2020 $2,806,700 +$1,954,700 +41% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q1
Q2 2019 $4,761,400 -$1,626,100 -52% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2021 Q1
Q2 2018 $3,135,300 -$1,001,200 -47% 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019 2020 Q1
Q2 2017 $2,134,100 -$463,100 -28% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2019 Q1
Q2 2016 $1,671,000 -$847,700 -103% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2018 Q1
Q2 2015 $823,300 +$188,500 +19% 01 Apr 2015 30 Jun 2015 10-Q 12 Aug 2016 2016 Q1
Q2 2014 $1,011,800 -$280,000 -38% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015 2016 Q1
Q2 2013 $731,800 -$435,600 -147% 01 Apr 2013 30 Jun 2013 10-Q 12 Aug 2014 2014 Q1
Q2 2012 $296,200 +$790,300 +73% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013 2013 Q1
Q2 2011 $1,086,500 -$761,180 -234% 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012 2012 Q1
Q2 2010 $325,320 01 Apr 2010 30 Jun 2010 10-Q 22 Aug 2011 2011 Q1

Vistagen Therapeutics, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $42,097,000 -$16,284,000 -63% 01 Apr 2024 31 Mar 2025 10-K 17 Jun 2025 2025 FY
2023 $25,813,000 +$23,903,000 +48% 01 Apr 2023 31 Mar 2024 10-K 17 Jun 2025 2025 FY
2022 $49,716,000 -$4,459,500 -9.9% 01 Apr 2022 31 Mar 2023 10-K 11 Jun 2024 2024 FY
2021 $45,256,500 -$33,183,000 -275% 01 Apr 2021 31 Mar 2022 10-K 28 Jun 2023 2023 FY
2020 $12,073,500 +$3,683,500 +23% 01 Apr 2020 31 Mar 2021 10-K 23 Jun 2022 2022 FY
2019 $15,757,000 -$1,229,500 -8.5% 01 Apr 2019 31 Mar 2020 10-K 29 Jun 2021 2021 FY
2018 $14,527,500 -$5,469,200 -60% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2020 FY
2017 $9,058,300 01 Apr 2017 31 Mar 2018 10-K 25 Jun 2019 2019 FY
2014 $2,768,900 -$642,900 -30% 01 Apr 2014 31 Mar 2015 10-K 29 Jun 2015 2015 FY
2013 $2,126,000 +$1,337,200 +39% 01 Apr 2013 31 Mar 2014 10-K 29 Jun 2015 2015 FY
2012 $3,463,200 +$102,600 +2.9% 01 Apr 2012 31 Mar 2013 10-K 25 Jun 2014 2014 FY
2011 $3,565,800 -$2,724,500 -324% 01 Apr 2011 31 Mar 2012 10-K 18 Jul 2013 2012 FY
2010 $841,300 01 Apr 2010 31 Mar 2011 10-K 02 Jul 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.